Genakumab not checked

Changchun GeneScience Pharmaceutical Co., Ltd. · GenSci048

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
9 in total
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first);…”In the company’s words, NCT06189495 on ClinicalTrials.gov
Tested for
Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD), Uveitis, Endometriosis-related Pain
Main trialPhase 2
“This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)”In the company’s words, NCT06189495 on ClinicalTrials.gov
Other names
GenSci048

Other drugs for Uveitis

All 9 drugs for Uveitis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Mar 2026 A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Phase 2Recruiting 14 Dec 2027 A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
Phase 2Recruiting 15 May 2028 A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
Phase 3Completed 3 Apr 2024 Safety & Efffficacy of Genakumab in Patients With Frequent Flares
Phase 2Completed 19 Jan 2024 A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
Phase 2Completed 28 Feb 2024 Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
Phase 1/2Completed 9 Jun 2022 Clinical Study of Genakumab for Injection in Patients With Acute Gout
Phase 1Completed 30 Nov 2023 Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults
Phase 1Completed 29 Nov 2024 A Bioequivalence Study of Two Different Dosage Form of Genakumab
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Genakumab

Following is part of Solo: you see every change to Genakumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in